Yogamet-GM 1 Forte Tablet is a combination oral hypoglycemic agent containing Glimepiride 1 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, acts by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves insulin sensitivity in peripheral tissues, enhancing glucose uptake and utilization. The synergistic action of these two agents provides effective glycemic control in patients inadequately managed by diet, exercise, and monotherapy. Yogamet-GM 1 Forte is particularly beneficial in patients with insulin resistance and those requiring combination therapy to achieve target glycemic levels. It is essential to monitor blood glucose regularly and adjust dosage based on therapeutic response and tolerability. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, primarily due to Metformin, while Glimepiride may cause hypoglycemia and weight gain. Caution is advised in patients with renal or hepatic impairment, and contraindications include diabetic ketoacidosis and severe renal dysfunction. Yogamet-GM 1 Forte should be used under medical supervision with appropriate lifestyle modifications for optimal diabetes management.